The estimated Net Worth of Robert A. Yedid is at least $66.4 Tisíc dollars as of 19 August 2022. Mr. Yedid owns over 26,240 units of Vaxart Inc stock worth over $35,114 and over the last 5 years he sold VXRT stock worth over $9,015. In addition, he makes $22,309 as Lead Independent Director at Vaxart Inc.
Sign up
Mr. Yedid VXRT stock SEC Form 4 insiders trading
Robert has made over 3 trades of the Vaxart Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 26,240 units of VXRT stock worth $24,666 on 19 August 2022.
The largest trade he's ever made was exercising 26,240 units of Vaxart Inc stock on 19 August 2022 worth over $24,666. On average, Robert trades about 4,180 units every 39 days since 2019. As of 19 August 2022 he still owns at least 37,355 units of Vaxart Inc stock.
You can see the complete history of Mr. Yedid stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Yedid biography
Robert A. Yedid serves as Lead Independent Director of the Company. He has served as a Managing Director at LifeSci Advisors, LLC, a global healthcare dedicated investor relations /public relations firm since 2014. From 2011 to 2014, Mr. Yedid served as a Managing Director at ICR Inc., in its healthcare investor relations. Mr. Yedid previously served as a portfolio manager of Hillhouse Capital Management and as a portfolio manager and senior research analyst at Principled Capital, with responsibility for health care investing. From 1999 to 2000, he was a Vice President at Warburg Pincus, a private equity and venture capital firm, investing in health care. Mr. Yedid began his career as an investment banker, including serving as a Managing Director in the healthcare finance group at Bear Stearns & Co. From 1999 to 2001, he served as a member of the board of directors of The Medicines Company and from 1999 to 2001, he was member of the board of directors of Eurand International S.p.a., an Italian-based specialty pharma company. Mr. Yedid earned a B.A. in Economics from Yale University and an M.B.A. from the Stanford University Graduate School of Business.
What is the salary of Robert Yedid?
As the Lead Independent Director of Vaxart Inc, the total compensation of Robert Yedid at Vaxart Inc is $22,309. There are 8 executives at Vaxart Inc getting paid more, with Wouter Latour having the highest compensation of $747,711.
How old is Robert Yedid?
Robert Yedid is 62, he's been the Lead Independent Director of Vaxart Inc since 2019. There are 2 older and 10 younger executives at Vaxart Inc. The oldest executive at Vaxart Inc is Anne VanLent, 72, who is the Independent Director.
What's Robert Yedid's mailing address?
Robert's mailing address filed with the SEC is C/O VAXART, INC., 170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Vaxart Inc
Over the last 7 years, insiders at Vaxart Inc have traded over $322,706,538 worth of Vaxart Inc stock and bought 8,979,091 units worth $2,899,807 . The most active insiders traders include Capital, Llc Armistice Capi..., Steven Lo a Wouter Latour. On average, Vaxart Inc executives and independent directors trade stock every 57 days with the average trade being worth of $1,309,363. The most recent stock trade was executed by W. Mark Watson on 18 June 2024, trading 20,000 units of VXRT stock currently worth $13,600.
What does Vaxart Inc do?
since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.
What does Vaxart Inc's logo look like?
Complete history of Mr. Yedid stock trades at Vaxart Inc
Vaxart Inc executives and stock owners
Vaxart Inc executives and other stock owners filed with the SEC include:
-
Wouter Latour,
Chairman of the Board -
Cezar Andrei Floroiu M.B.A.,
CEO, Pres, Principal Financial Officer & Director -
Dr. Sean N. Tucker,
Sr. VP & Chief Scientific Officer -
Margaret A. Echerd,
Sr. VP & Principal Accounting Officer -
Sean Tucker,
Chief Scientific Officer -
Margaret Echerd,
Principal Accounting Officer, Vice President, Controller -
Anne VanLent,
Independent Director -
Michael Finney,
Independent Director -
Robert Yedid,
Lead Independent Director -
Todd Davis,
Independent Director -
Karen Wilson,
Independent Director -
Keith Maher,
Director -
Steven Boyd,
Director -
Andrei Floroiu,
Chief Executive Officer, Principal Financial Officer, Director -
Edward B. Berg,
Sr. VP & Gen. Counsel -
John M. Harland M.B.A., CPA,
Consultant -
Dr. James F. Cummings M.D.,
Chief Medical Officer -
Dr. Rajesh Kapoor Ph.D.,
Sr. VP of Quality -
Dr. Richard M. Schwartz,
Sr. VP of Technical Operations -
Brant Biehn,
Sr. VP of Bus. Operations -
Shaily Jaini Garg,
Sr. VP of Clinical Devel. & Project Management -
Julie M Cherrington,
Director -
Edward B Berg,
SVP, General Counsel -
John M Harland,
Chief Financial Officer -
Richard J Markham,
Director -
Geoffrey F Cox,
Director -
John P Richard,
Director -
Phillip E Lee,
Chief Financial Officer -
David E. Wheadon,
Director -
James F. Cummings,
Chief Medical Officer -
W. Mark Watson,
Director -
Elaine J Heron,
Director -
Steven Lo,
President, Chief Exec Officer -
Fuad Ahmad,
Interim CFO